Prescription Drugs - Research and Data from KFF

Briefing on State Medicaid Programs, the Recession and Health Reform

Event Date: Sep 2, 2010

Event

The Kaiser Family Foundation's Commission on Medicaid and the Uninsured (KCMU) held a 9:30 a.m. ET briefing on Thursday, September 30 to examine the challenges facing states as they continue to struggle with the lingering impacts of the recession and begin preparing to implement health reform. Three reports were released at the event: Hoping for Economic Recovery, Preparing for Reform: A Look at Medicaid Spending, Coverage and Policy Trends: Results from a 50-State Medicaid Budget…

Key Facts About Medicare Part D Enrollment, Premiums, and Cost Sharing in 2024

Jul 2, 2024

Issue Brief

This brief analyzes 2024 Medicare Part D enrollment, premiums, and cost sharing. The analysis highlights the continued growth in Medicare Advantage enrollment in the Part D marketplace and substantially higher average monthly premiums for stand-alone Part D drug plan coverage. Changes to the Part D benefit included in the Inflation Reduction Act are helping to lower out-of-pocket costs for patients but could also contribute to higher-priced Part D coverage.

KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs

May 10, 2024

Feature

KFF’s latest Health Tracking Poll examines the public’s views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes. The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include Ozempic, Webovy and Mounjaro. This includes 6% who say they are currently taking one of the drugs.

KFF Health Tracking Poll: Economic Views and Experiences of Adults Who Struggle Financially

Feb 21, 2024

Feature

Half of adults say they have difficulty affording monthly bills or are just able to afford household expenses without having money left over. These groups overwhelmingly rate the economy negatively and are more likely to want 2024 presidential candidates to discuss economic issues.

What to Watch in 2024: The Latest Health Cost and Affordability Issues and Trends

Jan 24, 2024

News Release

While issues of health care costs and affordability may not be at the forefront of this year’s election issues, they remain a major concern among the public. About a quarter of Americans say they or a family member struggled to pay their medical bills just in the past year, and in recent KFF polling, voters said that health care affordability was very important to discuss in the election.KFF’s new brief describes the health cost and…

Poll: By a Wide Margin, Democratic Voters Now Care More About the Affordable Care Act Than Republican Voters Do, And Voters Trust Democrats More Than Republicans to Handle Its Future

Dec 1, 2023

News Release

The future of the Affordable Care Act, an issue that was once a key health care issue for Republican voters, is now more important to Democratic voters, a new KFF Health Tracking Poll finds. About half (49%) of voters say it is a “very important” issue for the candidates to discuss, including more than twice the share of Democratic voters (70%) than Republican voters (32%). Fielded prior to former President Donald Trump’s recent social media…

KFF Health Tracking Poll: Health Care Issues Emerge as Important Topics on 2024 Campaign Trail, Plus Concerns Loom Large Around Medicaid Unwinding

Dec 1, 2023

Feature

The future of the Affordable Care Act, once a key issue for Republican voters, is now of higher importance to Democratic voters. This KFF Health Tracking Poll also explores other important issues for candidates to discuss according to voters, Medicaid unwinding, Medicare drug-price provisions, and abortion as a voting issue.

More Than Six in Ten Large Firms Say GLP-1 Drug Coverage for Weight Loss Moderately or Significantly Impacted Their Prescription Drug Spending

Perspectives from Employers on the Costs and Issues Associated with Covering GLP-1 Agonists for Weight Loss

Oct 22, 2025

Issue Brief

While more large employers are covering GLP-1 drugs for weight loss, KFF's conversations with employers highlight concerns about the cost of these medications. Many of these employers have considered scaling back coverage of GLP-1 agonists for weight loss, or in some cases, employers are adding or strengthening coverage requirements.

Examining Short-Term Limited-Duration Health Plans on the Eve of ACA Marketplace Open Enrollment

Oct 15, 2025

Issue Brief

As Marketplace Open Enrollment nears, policy changes could leave millions of people facing substantially higher premiums and coverage loss, which could lead more consumers to purchase less expensive and less comprehensive coverage through short-term health plans. KFF analyzes short-term health policies sold by nine large insurers in 36 states, examining premiums, cost sharing, covered benefits, and coverage limitations and comparing them to ACA Marketplace plans.

Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity

Nov 26, 2024

Policy Watch

This policy watch examines the implications of new proposed regulations that would allow Medicare and require Medicaid to cover drugs used to treat obesity, including a relatively new class of highly effective but costly drugs known as GLP-1s.

Topics

Policy Research

Polling

Health News

Data & Features

For Media

About

View the Latest: Prescription Drugs

Filter